A recent Phase I/II trial confirmed the preliminary efficacy and tolerability of CAR NK cells derived from cord blood in heavily pretreated patients with CD19‐positive lymphoid cancers including two patients with refractory DLBCL.69 Here, CD19 is linked to diffuse large B-cell lymphoma.